Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150596 | 1.00 | L3MBTL1 (0.33) | L3MBTL1MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL10150441 | 1.00 | L3MBTL1 (0.33) | L3MBTL1MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL10150445 | 0.90 | ALDH1A1 (0.35) | L3MBTL1MAPTALDH1A1GAAHPGD | |
| SCHEMBL10150453 | 0.87 | MAPT (0.33) | MAPTKDM4EALDH1A1LMNAGLA | |
| SCHEMBL10150613 | 0.87 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL10150454 | 0.83 | HSP90AA1 (0.33) | — | |
| SCHEMBL10150593 | 0.81 | CRHR1 (0.36) | L3MBTL1MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL10150432 | 0.81 | CRHR1 (0.36) | L3MBTL1MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL12142624 | 0.81 | CRHR1 (0.36) | L3MBTL1MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL10150601 | 0.80 | CYP2C19 (0.39) | MAPTALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | L3MBTL1 4351/4885MAPT 1982/4885KDM4E 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.